These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18479730)

  • 1. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
    Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
    Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
    Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
    Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
    Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
    Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
    Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
    Ghaderi M; Strömberg O; Porwit A
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms.
    Sakr H; Clark Schneider K; Murugesan G; Bodo J; Hsi ED; Cook JR
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):147-152. PubMed ID: 27258562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPL W515L mutation in Chinese patients with myeloproliferative diseases.
    Xu W; Li JY; Xia J; Zhang SJ; Fan L; Qiao C
    Leuk Lymphoma; 2008 May; 49(5):955-8. PubMed ID: 18464114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
    Turakhia SK; Murugesan G; Cotta CV; Theil KS
    J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying JAK2 (V617F) mutation.
    Bock O; Hussein K; Neusch M; Schlué J; Wiese B; Kreipe H
    Eur J Haematol; 2006 Dec; 77(6):463-70. PubMed ID: 16930139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
    Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N
    Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients].
    Hu GY; Deng MY; Zhang GS; Luo YY; Zhu JF
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):394-8. PubMed ID: 19951533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.